Fig. 2

DNMT3B promotes miR-451a promoter methylation. a, DNMT3B expression in BCa and matched adjacent tissues in the Oncomine database; b, DNMT3B expression in normal and tumor tissues in TCGA databases predicted by the GEPIA website; c, the association between DNMT3B expression and the histological subtype of BC patients; d, the association between DNMT3B expression and the clinical stage of BC patients; e, the association between DNMT3B expression and the gender of BCa patients; f, DNMT3B mRNA expression in BCa cell lines T24, 5637, TCCSUP, UM-UC3 and SV-HUC-1 cells determined by RT-qPCR; g, DNMT3B protein expression in BCa cell lines T24, 5637, TCCSUP, UM-UC3 and SV-HUC-1 cells determined by western blot (full-length blots/gels are presented in Supplementary Figure 1A, B); h, the binding relationship between DNMT3B and miR-451a promoter in T24 and 5637 cells tested by ChIP-qPCR; i, promoter methylation in T24 cells in response to shDNMT3B (the top 3 haplotypes of high frequency were presented); j, promoter methylation in 5637 cells in response to shDNMT3B (the top 3 haplotypes of high frequency were presented); k, miR-451a expression in BCa cell lines in response to shDNMT3B determined by RT-qPCR. Data are represented as the means ± SD from three independent assays. Statistically significant differences were calculated using unpaired t-test (panel b), one-way (panel c and d) or two-way ANOVA (panel f-k), followed by Tukey’s multiple comparison test. *p < 0.05 vs tumor tissues, **p < 0.01 vs sh-NC or IgG treatment, ***p < 0.001 vs SV-HUC-1 cells